Demographic characteristics of study patients in the two treatment groups
| Adalimumab (n=36) | Infliximab (n=37) | p Value | |
| Age, median (IQR), years | 38 (27–47) | 37 (29–42) | 0.82 |
| Sex (F/M), % | 50/50 | 46/54 | 0.91 |
| Weight, kg | 69 (61–73) | 66 (61–71) | 0.38 |
| Disease duration, months | 167 (76–213) | 146 (116–218) | 0.66 |
| Time on infliximab, months | 32 (20–65) | 63 (33–85) | 0.07 |
| Concomitant immunosuppressives | 6 (AZA), 0 (MTX) | 0 (AZA), 2 (MTX) | 0.15 |
| Disease location (ileal/colonic/ileocolonic) | 3/7/26 | 7/11/19 | |
| Infliximab every 8 weeks at entry | 83% (30/36) | 76% (28/37) | 0.60 |
| Current smoker | 25% (9/36) | 30% (11/37) | 0.79 |
| CDAI baseline, median (IQR) | 48 (24–110) | 58 (34–122) | 0.51 |
| CRP baseline, median (IQR) | 3.3 (2.0–3.9) | 5.7 (1.8–6.9) | 0.53 |
CDAI, Crohn's Disease Activity Index; CRP, C-reactive protein.